<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789917</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE MucT003-16</org_study_id>
    <nct_id>NCT02789917</nct_id>
  </id_info>
  <brief_title>APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF</brief_title>
  <acronym>APPROACH</acronym>
  <official_title>APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesised that a dual therapy strategy by oral anticoagulation with the new&#xD;
      Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with&#xD;
      phenprocoumon plus acetylsalicylic acid (ASA) and clopidogrel with respect to avoiding&#xD;
      bleeding events in patients with atrial fibrillation undergoing percutaneous coronary&#xD;
      intervention in the setting of an acute coronary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with atrial fibrillation (AF) presenting an acute coronary syndrome (ACS) and&#xD;
      undergoing PCI require a triple therapy with a combination of oral anticoagulation (OAC) and&#xD;
      dual anti-platelet therapy. Current guidelines recommend a regimen consisting of aspirin,&#xD;
      clopidogrel and an oral anticoagulant. Although effective in preventing recurrent ischemia,&#xD;
      triple therapy confers an elevated bleeding risk, which also has a major impact on the&#xD;
      patients' prognosis and survival. Data from one randomized trial suggest that omitting&#xD;
      aspirin in patients with indication for triple therapy may reduce the risk of bleeding&#xD;
      without an increase of the rate of ischemic events. In addition, the recently introduced&#xD;
      non-vitamin-K oral anticoagulants (NOACs) show less bleeding events as compared to vitamin-K&#xD;
      antagonist in AF patients. In this trial it is postulated that a dual therapy consisting of&#xD;
      the factor-Xa inhibitor apixaban and clopidogrel is associated with significant lower&#xD;
      bleeding rates as compared to traditional triple therapy with aspirin, clopidogrel and a&#xD;
      vitamin K antagonist (VKA). To test this hypothesis, patients with atrial fibrillation, who&#xD;
      underwent PCI in the setting of an ACS will be randomized to either a dual therapy&#xD;
      (apixaban+clopidogrel) or a triple therapy (aspirin+clopiodgrel+VKA). The patients will be&#xD;
      followed-up for 6 months after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined endpoint of moderate or major bleeding complications during the initial hospitalization and follow up (Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding)</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined event of death, myocardial infarction, definite stent thrombosis, stroke/other systemic thromboembolism and all the individual components of the composite secondary endpoint</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications (Major bleeding: BARC &gt; 3b bleeding)</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Dual therapy (incl. NOAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban plus Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple therapy (incl. VKA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phrenprocoumon plus Clopidogrel plus ASA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dual Therapy</intervention_name>
    <description>Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.</description>
    <arm_group_label>Dual therapy (incl. NOAC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Triple Therapy</intervention_name>
    <description>HAS-BLED-Score &lt;3:&#xD;
Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.&#xD;
HAS-BLED-Score ≥ 3:&#xD;
Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months.</description>
    <arm_group_label>Triple therapy (incl. VKA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Patients with an ACS after successful percutaneous coronary intervention&#xD;
&#xD;
          -  Indication for oral anticoagulation due to non-valvular atrial fibrillation or atrial&#xD;
             flutter (CHA2DS2VASc score ≥ 2)&#xD;
&#xD;
          -  Males and Females, ages ≥ 18&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to&#xD;
             the start of study drug.&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  WOCBP must agree to follow instructions for method(s) of contraception for the&#xD;
             duration of treatment with study drugs plus 30 days (duration of ovulatory cycle)&#xD;
             post-treatment completion. However they must still undergo pregnancy testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  History of intracranial bleeding&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  History of TIMI major bleeding according to TIMI and/or type ≥3b BARC criteria in the&#xD;
             last 6 months&#xD;
&#xD;
          -  History of peptic ulcer in the last 6 months&#xD;
&#xD;
          -  Subjects with a history of a complicated or prolonged cardiogenic shock in the last&#xD;
             two weeks prior to randomization. A complicated or prolonged cardiogenic shock is&#xD;
             defined by a cardiogenic shock that required mechanical ventilation or the&#xD;
             cardiovascular support with positive inotropic drugs (i.v. catecholamine) for ≥7 days&#xD;
&#xD;
          -  Planned major surgery during the study course with planned discontinuation of&#xD;
             antithrombotic therapy&#xD;
&#xD;
          -  Expected life expectancy of less than a year and/or severe illness (e.g. malignancy)&#xD;
&#xD;
          -  Mechanical valve replacement&#xD;
&#xD;
          -  Valvular atrial fibrillation&#xD;
&#xD;
          -  Severe renal insufficiency (creatinine clearance &lt; 30ml/min)&#xD;
&#xD;
          -  Severe liver insufficiency (Child-Pugh-class C) or elevated hepatic transaminases &gt;2&#xD;
             times the upper limit of normal&#xD;
&#xD;
          -  Patient's inability to fully comply with the study protocol&#xD;
&#xD;
          -  Known or persistent abuse of medication, drugs or alcohol reliable by the investigator&#xD;
             in individual cases&#xD;
&#xD;
          -  Subjects with known contraindications to apixaban, phenprocoumon, clopidogrel or ASA&#xD;
             treatment, which are hypersensitive to the drug substance or any component of the&#xD;
             product&#xD;
&#xD;
          -  Relevant hematologic deviations: platelet count &lt; 50 G/L or platelet count &gt; 600 G/L&#xD;
&#xD;
          -  Current or planned pregnancy or nursing women, women 90 days after childbirth. Females&#xD;
             of childbearing potential, who do not use and are not willing to use medically&#xD;
             reliable methods of contraception for the entire study duration (such as oral,&#xD;
             injectable, or implantable contraceptives, or intrauterine contraceptive devices)&#xD;
             unless they are surgically sterilized / hysterectomized or there are any other&#xD;
             criteria considered sufficiently&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Wakili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München (LMU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universität München (LMU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Munich University Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herzzentrum am Universitätsklinikum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKHS Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augustinum</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München-Neuperlach</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Reza Wakili</investigator_full_name>
    <investigator_title>Professor Dr. med. Reza Wakili</investigator_title>
  </responsible_party>
  <keyword>ACS</keyword>
  <keyword>Triple-Therapy</keyword>
  <keyword>AF</keyword>
  <keyword>oral anticoagulation (OAC)</keyword>
  <keyword>non-vitamin-K oral anticoagulant (NOAC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Inclusion in central DZHK Database (German Centre for Cardiovascular Research)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

